TP53 and medulloblastoma: Furthermore, while our in vivo studies showed that 20 mg/kg of VMY administered three times per week for more than four weeks was well tolerated and was effective at treating a mouse model of SHH-driven medulloblastoma [14], a detailed investigation into the mechanism of VMY-induced cell death, and the role that p53 may play had not been explored.